Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

New Immunotherapy Drug Approved for Hodgkin Lymphoma

76 views

Published on

With a degree in mass communications and journalism from Kansas State University, Dawn Johnson went on to hold several leadership and marketing positions with San Antonio’s USAA financial services firm. Dawn Johnson also sits on the board of the San Antonio Clubhouse and the Leukemia and Lymphoma Society (LLS).

Published in: Health & Medicine
  • Be the first to comment

  • Be the first to like this

New Immunotherapy Drug Approved for Hodgkin Lymphoma

  1. 1. Dawn Johnson, San Antonio New Immunotherapy Drug Approved for Hodgkin Lymphoma
  2. 2. Introduction  With a degree in mass communications and journalism from Kansas State University, Dawn Johnson went on to hold several leadership and marketing positions with San Antonio’s USAA financial services firm. Dawn Johnson also sits on the board of the San Antonio Clubhouse and the Leukemia and Lymphoma Society (LLS). The LLS recently reported on a new type of immunotherapy that has been approved for patients with Hodgkin's lymphoma who are not responding to the common treatments. While Hodgkin's lymphoma is a generally treatable condition with an 88 percent or higher survival rate, this new drug, pembrolizumab, can help people who relapse or have limited treatment options. Pembrolizumab works by targeting PD-1, a protein that interacts with PD-L1 to prevent the immune system from recognizing and eliminating cancer cells. Hodgkin's lymphoma is the latest cancer to be successfully treated with this type of immunotherapy, which has already been approved to treat melanoma, one form of lung cancer, as well as head and neck cancer.

×